A new paraplegin mutation in a patient with primary progressive multiple sclerosis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 24 03 2020
revised: 08 06 2020
accepted: 11 06 2020
pubmed: 23 6 2020
medline: 15 5 2021
entrez: 23 6 2020
Statut: ppublish

Résumé

Primary progressive multiple sclerosis (PPMS) presents with clinical signs of slowly progressive long tract dysfunction that can overlap with neurodegenerative disorders, such as hereditary spastic paraplegia (HSP). Herein, we present two siblings in whom we have identified a novel mutation in the paraplegin (SPG7) gene. The proband, a 49-year-old woman, presented with a five-year history of progressive spastic paraparesis and ataxia. Brain MRI showed mild cerebellar atrophy. The genetic study revealed a homozygous mutation in the SPG7 gene, that led to the diagnosis of HSP. Four years previously, the younger brother had complained of slowly progressive spastic-ataxic gait, that started one year before; MRI had disclosed multiple areas of white matter hyperintensity with contrast enhancement. A diagnosis of active PPMS was made, and the patient started Disease-Modifying Therapy with further clinical and radiological stability. Once a genetic diagnosis was achieved in his sister, the patient underwent SPG7 testing, which disclosed the same mutation. Whether MS is a mimicry of HSP or it represents "double trouble" condition in this patient, it remains undetermined.

Identifiants

pubmed: 32570181
pii: S2211-0348(20)30378-3
doi: 10.1016/j.msard.2020.102302
pii:
doi:

Substances chimiques

Metalloendopeptidases EC 3.4.24.-
ATPases Associated with Diverse Cellular Activities EC 3.6.4.-

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102302

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Angelo Bellinvia (A)

Department of NEUROFARBA, Section Neurosciences, University of Firenze, Firenze, Italy.

Luisa Pastò (L)

Department of Neurological Rehabilitation, AOU Careggi, Firenze, Italy.

Claudia Niccolai (C)

IRCCS Don Carlo Gnocchi, Firenze, Italy.

Alessandra Tessa (A)

Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Fondazione Stella Maris, Pisa, Italy.

Riccardo Carrai (R)

Department of Neurophysiopathology, AOU Careggi, Firenze, Italy.

Cristiana Martinelli (C)

Department of Neurophysiopathology, AOU Careggi, Firenze, Italy.

Marco Moretti (M)

Department of Neuroradiology, AOU Careggi, Firenze, Italy.

Maria Pia Amato (MP)

Department of NEUROFARBA, Section Neurosciences, University of Firenze, Firenze, Italy; IRCCS Don Carlo Gnocchi, Firenze, Italy.

Filippo Maria Santorelli (FM)

Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Fondazione Stella Maris, Pisa, Italy.

Sandro Sorbi (S)

Department of NEUROFARBA, Section Neurosciences, University of Firenze, Firenze, Italy; IRCCS Don Carlo Gnocchi, Firenze, Italy.

Sabrina Matà (S)

Department of Neurology, AOU Careggi, Largo Palagi 1, Firenze 50139, Italy. Electronic address: sabrina.mata@aouc.unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH